AstraZeneca est l'une des plus grandes sociétés pharmaceutiques en Europe, combinant des portefeuilles robustes en oncologie et médicaments respiratoires avec un pipeline R&D leader dans l'industrie.
AstraZeneca est un leader pharmaceutique mondial avec un portefeuille solide en oncologie, thérapies cardiovasculaires et respiratoires, générant de manière constante une croissance des revenus supérieure à la moyenne du secteur.
Data updated Feb 15 · Source: Twelve Data
AstraZeneca has established itself as one of the world's premier biopharmaceutical companies, with a robust oncology pipeline that drives much of its growth narrative. The stock has delivered extraordinary performance, trading near its 52-week high of $206.71 with remarkable gains across all timeframes " up over 176% year-over-year and 308% over five years.
The bull case centers on AZN's industry-leading oncology franchise (Tagrisso, Imfinzi, Enhertu), expanding rare disease portfolio via the Alexion acquisition, and consistent revenue growth. Management has targeted $80 billion in revenue by 2030, an ambitious but credible goal given pipeline depth.
However, the bear case warrants attention. The P/E ratio of 34.55 is elevated for a large-cap pharma, pricing in significant future growth. Key patent expirations loom in the late 2020s, and the recent price surge may leave limited near-term upside. Regulatory and pricing pressures across global markets remain persistent headwinds.
AstraZeneca is a high-quality pharmaceutical holding, though current valuations suggest investors should consider entry points carefully. The pipeline strength and diversification provide a solid long-term foundation.
Latest from Otrai
A stock index is a single number that summarizes the price action of a basket of companies. The S&P 500 tracks roughly 500 large US firms, the Nasdaq-100 tracks the 100 largest non-financial names on the Nasdaq exchange, and the Dow Jones Industrial Average follows 30 blue-chip stocks.
The Greeks explain why an option costs what it costs and how that price changes when the stock moves, time passes, and volatility shifts. Delta, Gamma, Theta, and Vega, made accessible.
Chart patterns are the most recognizable part of technical analysis and the most misunderstood. Most fail or break out the wrong way before reversing. This guide covers head and shoulders, double tops and bottoms, triangles, and flags — with realistic reliability, target measurement, and false-breakout confirmation.
Chaque trader a une stratégie qui semble excellente dans sa tête. Le backtesting est la façon de découvrir si cela fonctionne réellement. Voici comment tester les stratégies correctement, quelles métriques comptent et pourquoi la plupart des résultats de backtesting sont trop beaux pour être vrais.
Powered by Rexiew